Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis

Table 1 Characteristics of the included studies

Study	Patient’s country	Ethnicity	Year	Time of collection	Pathological stage	Method	Number of patients	Age in years	Follow-up months	Cut-off for CD44 positive	Survival analysis
Endo et al. [18]	Japan	Asian	2000	ND	ND	IHC	107	17–80	80	>0 % staining	OS
Huang et al. [22]	China	Asian	2001	1995–1999	I–IV	IHC	51	36–72	48	>0 % staining	OS
Su et al. [27]	China	Asian	2006	1996–1999	I–IV	IHC	40	32–70	36	>0 % staining	OS
Yang et al. [28]	China	Asian	2008	1997–2000	I–IV	IHC	302	26–75	121	>10 % staining	OS; DFS
Zhang et al. [21]	China	Asian	2008	2001–2004	I–IV	IHC	50	21–68	ND	>20 % staining	OS
Peng et al. [23]	China	Asian	2010	2005–2006	ND	IHC	76	19–69	36	>25 % staining	OS
Ryu et al. [17]	Korea	Asian	2011	1990–2003	I–IV	IHC	260	ND	137	>10 % staining	OS; DFS
Tovuu et al. [25]	Japan	Asian	2012	2005–2009	I–IV	RT–PCR	48	ND	48	Median	OS; DFS
Mima et al. [16, 19]	Japan	Asian	2012	2004–2007	I–IV	IHC	150	ND	60	>0 % staining	OS; DFS
Zhou et al. [24]	China	Asian	2012	2007–2010	I–III	RT–PCR	323	ND	74	Median	OS; DFS
Mima et al. [16, 19]	Japan	Asian	2012	2004–2007	I–IV	IHC	235	ND	60	>50 % staining	OS; DFS
Chen et al. [26]	China	Asian	2014	2005–2008	I–IV	IHC	387	ND	96	>10 % staining	OS
Cao et al. [29]	China	Asian	2014	2005–2011	ND	IHC	46	22–79	85	>25 % staining	OS
Hu et al. [20]	China	Asian	2014	2006–2007	I–III	IHC	160	29–72	84	>10 % staining	OS; DFS

ISSN: 1475-2867